(MedPage Today) — BERLIN — The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different HER2-positive early-stage breast cancer settings in back-to-back randomized clinical trials.
In…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118025
Author :
Publish date : 2025-10-19 21:42:00
Copyright for syndicated content belongs to the linked Source.
